CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE
|
CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
XARELTO Market Size, Forecast, and Market Insight to 2032, with Focus on the United States and Japan
04 avr. 2024 11h13 HE
|
Research and Markets
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "XARELTO Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
28 déc. 2023 07h00 HE
|
CytoSorbents
CytoSorbents Provides Update on STAR-T Trial and Final Independent DSMB Recommendation
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
27 sept. 2023 07h00 HE
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
01 sept. 2023 16h43 HE
|
CytoSorbents
PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
07 juil. 2023 07h07 HE
|
CytoSorbents
PRINCETON, N.J., July 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood...
CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
20 avr. 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
07 mars 2023 07h00 HE
|
CytoSorbents
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Aronora Announces Clinical Data to Be Presented at the 63rd American Society of Hematology Annual Meeting
06 déc. 2021 08h00 HE
|
Aronora, Inc
PORTLAND, Ore., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing innovative therapies for hematologic diseases, today announced that clinical data...
UCHealth is Colorado's first health system to implant new device to prevent strokes
23 févr. 2016 11h08 HE
|
UCHealth
AURORA, Colo., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Heart specialists at UCHealth's Medical Center of the Rockies and University of Colorado Hospital are the first in the region to implant a new device...